Key facts
- This page summarizes Robert Michael Floyd's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Feb 2023, 16:22.
Robert Michael Floyd - 09 Feb 2023 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- PCSA
- Reported as of
- 09 Feb 2023
- Net transaction value
- +$8,000
- SEC form
- 4
- Accepted by SEC
- 10 Feb 2023, 16:22:45 UTC
- Prior SEC filing
- 04 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Michael Floyd filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 10 Feb 2023.
Change
- Previous filing in this sequence was filed on 04 Jan 2023.
- Current net transaction value: +$8,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Award
- Transaction value
- $8,000
- Shares
- +10,000
- Change %
- +14%
- Price
- $0.8000
- Shares after
- 82,267
- Date
- 09 Feb 2023
- Ownership
- Direct
PCSA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 89,794
- Date
- 09 Feb 2023
- Ownership
- by Elion Oncology, Inc.
* marks a reported price that did not pass the local price check.